Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global mRNA vaccines for animals market was valued at USD 18.4 million in 2024 and is projected to reach USD 37.8 million by 2031, exhibiting a CAGR of 11.0% during the forecast period.
mRNA vaccines for animals represent a novel approach in veterinary medicine, utilizing messenger RNA technology to stimulate immune responses against specific pathogens. These vaccines work by delivering synthetic mRNA encoding viral or bacterial antigens into animal cells, enabling the immune system to recognize and combat targeted diseases. Compared to traditional vaccines, mRNA vaccines offer significantly faster development timelines, improved efficacy rates, and enhanced adaptability to emerging animal disease variants. The technology is particularly valuable for zoonotic disease control and livestock protection, with applications extending to companion animals, poultry, and livestock sectors.
The market growth is primarily driven by increasing zoonotic disease surveillance, rising pet ownership in developed regions, and advancements in synthetic biology. The COVID-19 pandemic demonstrated the rapid deployment capability of mRNA platforms, which accelerated veterinary applications. Regulatory agencies like the USDA and EMA have established pathways for mRNA veterinary vaccine approval, with several candidates entering clinical trials. Market leaders including Merck Animal Health and Boehringer Ingelheim have announced significant investments in mRNA vaccine production facilities, indicating strong industry confidence in the technology's commercial viability.
Rapid Disease Outbreak Response Capability
The mRNA vaccine platform offers unprecedented speed in vaccine development, enabling rapid response to emerging zoonotic diseases and animal pandemics. This capability is crucial for controlling outbreaks like avian influenza or African swine fever, where traditional vaccine platforms would require months longer to develop.
Superior Immune Response Activation
mRNA vaccines elicit both humoral and cellular immune responses, providing animals with more comprehensive protection compared to traditional vaccines. The technology enables precise antigen design, resulting in higher efficacy rates of 92-97% in clinical trials across multiple species.
The global push for sustainable livestock farming is driving adoption of mRNA vaccines that reduce antibiotic use by 65-80% compared to conventional treatments
With mRNA vaccines enabling more precise immune targeting, livestock producers achieve better herd health management while meeting increasing consumer demands for antibiotic-free meat products.
MARKET CHALLENGES
High Initial Development Costs
Developing mRNA vaccines requires significant upfront investment in research and development, with initial costs ranging from $50-100 million per vaccine candidate. This includes costs of lipid nanoparticle optimization, preclinical studies, and regulatory compliance documentation, creating barriers for smaller pharmaceutical companies.
Other Challenges
Cold Chain Requirements
Most mRNA vaccines require storage at -20°C to -70°C, creating significant logistical challenges for distribution in remote or underdeveloped regions. Maintaining cold chain integrity adds 25-40% to distribution costs compared to conventional vaccines.
Regulatory Pathway Uncertainties
Despite promising clinical results, the regulatory pathway for mRNA vaccines in veterinary medicine remains complex and varies significantly across different regions. The EMA and FDA have different requirements for gene therapy products, creating uncertainty for manufacturers targeting multiple markets simultaneously. Full approval processes typically require 3-5 years and $15-25 million in regulatory costs alone.
Personalized Veterinary Medicine Expansion
The mRNA vaccine platform enables rapid customization for specific pathogen strains, making it ideal for creating region-specific or even farm-specific vaccine formulations. This capability opens new markets for personalized veterinary medicine, projected to reach $850 million by 2028 for companion animals alone.
| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Multivalent Vaccines demonstrate superior market adoption due to their ability to provide comprehensive protection against multiple disease strains in a single administration, significantly reducing the need for multiple injections and simplifying vaccination protocols for veterinary practitioners. |
| By Application |
|
Infectious Diseases application dominates due to the immediate and critical need to control outbreaks in animal populations, particularly in high-density farming environments where rapid transmission can cause substantial economic losses, making this segment the primary driver for mRNA vaccine adoption. |
| By End User |
|
Livestock Farms represent the most significant end-user segment due to the economic imperative of disease prevention in high-value animal production systems, where mRNA vaccines offer rapid development and deployment advantages over traditional vaccines, especially for emerging disease threats. |
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
Zoetis Inc. (USA) leads the mRNA vaccines for animals market with its extensive distribution network and diverse product portfolio for companion animals and livestock. The company's strategic partnerships with research institutions have strengthened its position in developing next-generation mRNA vaccines for emerging animal diseases.
Elanco Animal Health (USA) and Merck Animal Health (USA) follow closely, leveraging their established presence in veterinary pharmaceuticals to capture significant market share through innovative delivery systems and combination vaccines.
Boehringer Ingelheim (Germany) and Ceva Santé Animale (France) focus on expanding their presence in emerging markets through localized production facilities and strategic acquisitions of smaller biotech firms specializing in mRNA technology.
Vetoquinol (France) and Virbac (France) concentrate on developing temperature-stable mRNA vaccines for tropical markets, while also investing in automated manufacturing processes to reduce production costs.
List of Key mRNA Vaccines for Animals Companies ProfiledZoetis Inc. (USA)
Elanco Animal Health (USA)
Merck Animal Health (USA)
Boehringer Ingelheim (Germany)
Ceva Santé Animale (France)
Vetoquinol (France)
Virbac (France)
The mRNA vaccine market for animals is experiencing significant growth as pharmaceutical companies adapt human vaccine technology for veterinary applications. Major players are investing heavily in developing mRNA-based solutions for livestock diseases, companion animal health, and zoonotic disease prevention. This expansion is driven by the need for more effective and rapidly deployable vaccines compared to traditional approaches.
Market analysis indicates the global animal health market will reach $45 billion by 2028, with mRNA vaccines capturing an increasing share. Current R&D focuses on developing multivalent vaccines that can protect against multiple strains with single administration, particularly for rapidly mutating viruses in livestock populations.
Other TrendsRegional Market Development
North America currently leads in mRNA vaccine development for animals, with both established pharmaceutical companies and startups securing significant funding rounds. European markets are following closely with increased regulatory support for innovative veterinary medicines. Asia-Pacific markets show the fastest growth rate as emerging economies invest in advanced veterinary healthcare infrastructure.
The technology enables development of region-specific vaccines addressing local disease challenges. Companies are developing platforms that can be quickly adapted to emerging threats, reducing development time from years to months. This responsiveness is particularly valuable for outbreak management in densely populated animal farming operations.
Recent advancements include temperature-stable formulations that overcome previous cold chain limitations, significantly improving distribution capabilities in developing markets. Several companies have announced successful field trials with efficacy rates exceeding 90% across multiple species, accelerating regulatory approval processes in key markets.
Regional Analysis: mRNA Vaccines for Animals MarketEurope
Europe represents a mature market for veterinary pharmaceuticals with strong regulatory oversight. The European Medicines Agency provides clear guidance for veterinary biologics, facilitating development of mRNA vaccines for companion animals and livestock. EU member states collaborate on animal health initiatives, with northern countries showing particular strength in veterinary research. The region's emphasis on animal welfare and food security drives investment in advanced vaccine technologies, though market growth faces some constraints from competition with established vaccine producers.
Asia-Pacific
Asia-Pacific demonstrates the fastest growth potential for mRNA veterinary vaccines, driven by increasing pet ownership and livestock production. Japan and South Korea lead in technology adoption, while Southeast Asian markets show rapid expansion. Australia's strong research sector contributes to regional advancement. The region benefits from technology transfer agreements with North American and European partners, though intellectual property considerations sometimes limit collaboration. Distribution networks continue to improve, enabling wider access to advanced veterinary medicines.
South America
South America's market focuses primarily on livestock health, with Brazil and Argentina representing the largest markets. Emerging infectious diseases drive demand for advanced vaccines, though economic instability in some areas limits investment. The region shows growing interest in mRNA technologies for zoonotic disease prevention and food animal health. Regulatory harmonization across Mercosur countries facilitates market growth, though infrastructure challenges remain in distribution to remote areas.
Middle East & Africa
The Middle East and Africa show emerging interest in advanced veterinary medicine, particularly for high-value animals and zoonosis control. South Africa leads in research capabilities, while Gulf states invest in advanced veterinary infrastructure. The regions face challenges in distribution and cold chain requirements for mRNA vaccines. However, increasing focus on one-health initiatives and pandemic preparedness drives investment in novel vaccine platforms, with international partnerships facilitating technology transfer and local production initiatives.
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
極By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Veterinary pharmaceutical and biotech companies
Animal health product manufacturers
Livestock producers and farm operators
Veterinary clinics and animal hospitals
Investors, consultants, and regulatory agencies
-> Global mRNA vaccines for animals market was valued at USD 18.4 million in 2024 and is projected to reach USD 37.8 million by 2031.
-> The market is expected to exhibit a compound annual growth rate (CAGR) of 11.0% during the forecast period from 2024 to 2031.
-> mRNA vaccines for animals are veterinary vaccines that use messenger RNA technology to stimulate an immune response against specific pathogens in livestock, pets, and other animals by delivering synthetic mRNA encoding viral or bacterial antigens.
-> The U.S. market is estimated at $ million in 2024, while China is projected to reach $ million by 2031.
-> The market is segmented into Injectable Drug Administration and Non-invasive Drug Administration types.
Our Clients
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates